Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Failure, Chronic | 19 | 2024 | 941 | 3.050 |
Why?
|
| Peritoneal Dialysis | 9 | 2024 | 131 | 2.350 |
Why?
|
| Renal Dialysis | 14 | 2024 | 952 | 1.400 |
Why?
|
| Catheters, Indwelling | 4 | 2024 | 150 | 1.190 |
Why?
|
| Catheter-Related Infections | 6 | 2024 | 137 | 0.970 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 850 | 0.920 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 2 | 2020 | 22 | 0.780 |
Why?
|
| Hydrothorax | 1 | 2020 | 11 | 0.650 |
Why?
|
| Calcimimetic Agents | 1 | 2019 | 5 | 0.630 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2019 | 17 | 0.620 |
Why?
|
| Kidney Transplantation | 4 | 2023 | 572 | 0.480 |
Why?
|
| Renal Insufficiency | 4 | 2024 | 252 | 0.450 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2019 | 53 | 0.430 |
Why?
|
| Latent Tuberculosis | 1 | 2014 | 76 | 0.410 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2014 | 89 | 0.400 |
Why?
|
| Child | 26 | 2024 | 26332 | 0.390 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 92 | 0.330 |
Why?
|
| Catheterization | 3 | 2022 | 234 | 0.300 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2023 | 84 | 0.300 |
Why?
|
| Renal Replacement Therapy | 3 | 2023 | 161 | 0.300 |
Why?
|
| Nephrosis, Lipoid | 1 | 2009 | 11 | 0.300 |
Why?
|
| Nephrotic Syndrome | 1 | 2009 | 52 | 0.290 |
Why?
|
| Cost Savings | 1 | 2008 | 78 | 0.280 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 213 | 0.280 |
Why?
|
| Oxygen | 2 | 2021 | 553 | 0.260 |
Why?
|
| Infant | 11 | 2024 | 13332 | 0.260 |
Why?
|
| Ascitic Fluid | 2 | 2017 | 29 | 0.260 |
Why?
|
| Humans | 35 | 2024 | 131967 | 0.240 |
Why?
|
| Child, Preschool | 12 | 2024 | 15066 | 0.240 |
Why?
|
| Hypertension | 2 | 2019 | 1362 | 0.240 |
Why?
|
| Adolescent | 17 | 2024 | 21008 | 0.240 |
Why?
|
| Health Care Costs | 1 | 2008 | 400 | 0.230 |
Why?
|
| Peritonitis | 2 | 2024 | 75 | 0.220 |
Why?
|
| Acute Kidney Injury | 2 | 2024 | 690 | 0.220 |
Why?
|
| Retrospective Studies | 12 | 2023 | 17703 | 0.220 |
Why?
|
| Nephrology | 2 | 2016 | 156 | 0.210 |
Why?
|
| Observer Variation | 1 | 2024 | 319 | 0.200 |
Why?
|
| Pruritus | 1 | 2023 | 50 | 0.200 |
Why?
|
| Kidney | 3 | 2023 | 1304 | 0.190 |
Why?
|
| Oximetry | 2 | 2021 | 177 | 0.190 |
Why?
|
| Male | 21 | 2024 | 65357 | 0.190 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 33 | 0.180 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 104 | 0.180 |
Why?
|
| Ureter | 1 | 2023 | 97 | 0.180 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 55 | 0.180 |
Why?
|
| Brain Chemistry | 1 | 2021 | 111 | 0.170 |
Why?
|
| Standard of Care | 2 | 2019 | 135 | 0.160 |
Why?
|
| Hematocrit | 1 | 2020 | 108 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 259 | 0.160 |
Why?
|
| Blood | 1 | 2020 | 100 | 0.160 |
Why?
|
| Veins | 1 | 2020 | 99 | 0.160 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2020 | 57 | 0.160 |
Why?
|
| Female | 16 | 2024 | 71316 | 0.150 |
Why?
|
| Infant Formula | 1 | 2020 | 104 | 0.150 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 169 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 99 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2019 | 393 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 109 | 0.140 |
Why?
|
| Creatinine | 1 | 2020 | 402 | 0.140 |
Why?
|
| Infant, Newborn | 7 | 2024 | 8604 | 0.140 |
Why?
|
| Bacteremia | 1 | 2022 | 428 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 359 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 58 | 0.140 |
Why?
|
| Pediatrics | 3 | 2019 | 1239 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 141 | 0.140 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 139 | 0.140 |
Why?
|
| Arterial Pressure | 1 | 2019 | 131 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 331 | 0.140 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 83 | 0.140 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2017 | 9 | 0.140 |
Why?
|
| Sevelamer | 1 | 2017 | 11 | 0.140 |
Why?
|
| Hyperphosphatemia | 1 | 2017 | 19 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 542 | 0.130 |
Why?
|
| Hemodiafiltration | 1 | 2017 | 17 | 0.130 |
Why?
|
| Chelating Agents | 1 | 2017 | 51 | 0.130 |
Why?
|
| Chylous Ascites | 1 | 2017 | 10 | 0.130 |
Why?
|
| Milk, Human | 1 | 2020 | 318 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 568 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2021 | 357 | 0.130 |
Why?
|
| Heart | 1 | 2021 | 676 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2023 | 13011 | 0.120 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 143 | 0.120 |
Why?
|
| Peritoneum | 1 | 2016 | 38 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 222 | 0.120 |
Why?
|
| Texas | 3 | 2017 | 3629 | 0.120 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 129 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2019 | 708 | 0.110 |
Why?
|
| Quality of Life | 2 | 2023 | 2116 | 0.110 |
Why?
|
| Sepsis | 1 | 2019 | 501 | 0.110 |
Why?
|
| Risk Factors | 4 | 2018 | 10998 | 0.110 |
Why?
|
| Public Policy | 1 | 2015 | 54 | 0.110 |
Why?
|
| Urogenital Abnormalities | 1 | 2016 | 161 | 0.110 |
Why?
|
| Skin Tests | 1 | 2014 | 100 | 0.110 |
Why?
|
| Young Adult | 5 | 2019 | 10108 | 0.100 |
Why?
|
| Hyperammonemia | 1 | 2013 | 60 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1027 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 721 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2014 | 482 | 0.080 |
Why?
|
| Transplant Recipients | 2 | 2022 | 233 | 0.080 |
Why?
|
| Incidence | 1 | 2018 | 3352 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2009 | 5122 | 0.070 |
Why?
|
| Glomerular Mesangium | 1 | 2009 | 19 | 0.070 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 775 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5298 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2009 | 130 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 420 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 310 | 0.070 |
Why?
|
| Blood Pressure Determination | 1 | 2008 | 119 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 432 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 393 | 0.070 |
Why?
|
| Age Factors | 3 | 2021 | 2869 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 220 | 0.070 |
Why?
|
| Adult | 3 | 2023 | 31734 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 441 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 544 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 3095 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3425 | 0.060 |
Why?
|
| Biopsy | 1 | 2009 | 1252 | 0.060 |
Why?
|
| United States | 2 | 2018 | 11827 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 666 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2008 | 800 | 0.050 |
Why?
|
| Nitrogen | 1 | 2024 | 122 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 228 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2024 | 300 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3843 | 0.040 |
Why?
|
| Hypoxia, Brain | 1 | 2021 | 34 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2021 | 102 | 0.040 |
Why?
|
| Living Donors | 1 | 2022 | 117 | 0.040 |
Why?
|
| Blood Volume | 1 | 2021 | 71 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 6522 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2020 | 88 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 466 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2019 | 18 | 0.040 |
Why?
|
| Renal Veins | 1 | 2019 | 33 | 0.040 |
Why?
|
| Iliac Vein | 1 | 2019 | 28 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 52 | 0.040 |
Why?
|
| Vascular Grafting | 1 | 2019 | 48 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 53 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 72 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 532 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 175 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 215 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 335 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2022 | 562 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 487 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 222 | 0.030 |
Why?
|
| Arteries | 1 | 2019 | 210 | 0.030 |
Why?
|
| Iohexol | 1 | 2017 | 19 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 443 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2017 | 30 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2021 | 819 | 0.030 |
Why?
|
| Nephrology Nursing | 1 | 2016 | 2 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1519 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 57 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 28 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 76 | 0.030 |
Why?
|
| Myocardium | 1 | 2021 | 876 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 251 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2020 | 494 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 813 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 616 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 530 | 0.030 |
Why?
|
| Echocardiography | 1 | 2021 | 1138 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2308 | 0.030 |
Why?
|
| Government | 1 | 2015 | 13 | 0.030 |
Why?
|
| Foundations | 1 | 2015 | 23 | 0.030 |
Why?
|
| Thrombosis | 1 | 2019 | 495 | 0.030 |
Why?
|
| Triglycerides | 1 | 2017 | 605 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 372 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 955 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 492 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 589 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 777 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 1714 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1307 | 0.020 |
Why?
|
| Reoperation | 1 | 2016 | 844 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2016 | 558 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 781 | 0.020 |
Why?
|
| Body Weight | 1 | 2016 | 990 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1916 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3415 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 701 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1228 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 555 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2863 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3135 | 0.010 |
Why?
|